News ( Year: 2018 )

SORT BY YEAR
8 May, 2018

Ally Bridge Portfolio News – WUXI APPTEC PRICES A-Share IPO

Hong Kong and Shanghai, May 8, 2018 / BioCentury / – – Services and manufacturing company WuXi AppTec Co. Ltd. (Shanghai:603259) raised RMB2.3 billion ($354 million) through the sale of 104.2 million shares at RMB21.60 in an IPO underwritten by Huatai and Guotai Junan. The price values WuXi at RMB22.5 billion ($3.5 billion), based on […]

Read More
27 March, 2018

Ally Bridge Portfolio News – Hua Medicine Raises $117.4 Million in Series D & Series E Financing

Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of US$ 117.4 million. The financing included new investors Blue Pool Capital Limited, GIC Private Limited, AVICT Global, 6 Dimensions Capital, Adrian Cheng (via K11 Investments), […]

Read More
21 March, 2018

Ally Bridge Portfolio News – Boston Scientific Announces Agreement To Acquire NxThera

Acquisition expands portfolio with minimally invasive treatment option for patients with benign prostatic hyperplasia MARLBOROUGH, Mass., March 21, 2018 /PRNewswire/ — Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States (U.S.) […]

Read More
8 January, 2018

Ally Bridge Group and LifeTech Scientific Form China-Global Medtech Investment and Operating Partnership

Hong Kong, Shenzhen and San Francisco, January 7, 2018 – Ally Bridge Group (“ABG”), a global healthcare-focused investment firm, has entered into a strategic partnership with LifeTech Scientific Corporation (SEHK: 1302), a leading innovative medical device company in China, to focus on investing in some of the world’s leading medtech companies and helping them to […]

Read More